TRT and the 'over 40' optimization trend: what's real?

What did @ryanover40prime actually say?

He made a straightforward argument: TRT and a peptide called Tirzepatide (which he calls "Reddit TrueTide") are tools, not shortcuts. His analogy is that using a calculator doesn't mean you didn't do the math. He also listed his actual work: daily gym sessions, 15,000 steps, high protein intake, and structured dieting. The core claim is that critics dismissing his results are projecting their own insecurities onto him.

To be clear about what this video is and isn't. It's not a medical guide. It's a motivational post from someone who's been on TRT for four years and is now layering in a GLP-1 receptor agonist during a cut. He isn't telling you to do what he's doing. He's defending what he's doing.

Does the science back this up?

On the core behavioral claim, yes. The idea that TRT alone doesn't produce dramatic physique changes without lifestyle work is well-supported. Where it gets more complicated is the combined effect of TRT plus a GLP-1 agonist like Tirzepatide alongside aggressive training.

Testosterone replacement in hypogonadal men does increase lean mass and reduce fat mass, but the effect sizes are modest without resistance training. A landmark meta-analysis by Bhasin et al. (2001, New England Journal of Medicine) showed dose-dependent increases in fat-free mass with testosterone, but gains were significantly amplified when combined with exercise. More recently, Finkelstein et al. (2013, NEJM) showed that testosterone alone produced measurable body composition changes, but diet and activity remained strong independent variables.

On Tirzepatide: the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed 20-22% body weight reduction in non-diabetic adults over 72 weeks, but participants also followed a reduced-calorie diet and increased activity. The drug doesn't do the work alone.

His claim that "they don't see" the effort behind the results is behaviorally accurate. Research on attribution bias consistently shows people externalize others' success to situational factors while internalizing their own, a pattern documented in social psychology going back to Jones and Nisbett (1971).

What did they get wrong (or right)?

Mostly right, with one important omission that matters for anyone watching this as health guidance.

He's correct that TRT and GLP-1 agonists are tools, not magic. The science is clear that both work significantly better alongside structured diet and exercise. His numbers, 150 to 200 grams of protein daily, 15,000 steps, daily resistance training, are all consistent with evidence-based body recomposition protocols.

What he doesn't mention, and this matters, is that neither TRT nor Tirzepatide is appropriate for everyone, and combining them introduces pharmacological complexity. TRT in eugonadal men (men with normal testosterone levels) is not the same as TRT in clinically diagnosed hypogonadism. The Endocrine Society guidelines (Bhasin et al., 2018) are specific about this distinction.

His framing of "tools available to me" also glosses over access. These are prescription medications requiring clinical oversight, regular bloodwork, and ongoing monitoring. Framing them as equivalent to a calculator is motivationally catchy but medically incomplete.

That said, his core point stands. Attribution that ignores effort is unfair, and the research on hypogonadal men shows that lifestyle factors remain significant predictors of outcome even on TRT.

What should you actually know?

If you're watching this and wondering whether TRT or Tirzepatide could work for you, the answer requires a real clinical evaluation, not a TikTok comparison. TRT is indicated for men with clinically low testosterone confirmed by bloodwork, with symptoms. It is not a general performance enhancement tool, and prescribing it outside of clinical indications carries documented risks including erythrocytosis, sleep apnea exacerbation, and cardiovascular considerations flagged in FDA labeling.

Tirzepatide is a dual GIP/GLP-1 receptor agonist currently FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Its use in body recomposition outside those indications is off-label. Compounded versions are not equivalent to brand-name formulations, and anyone using compounded Tirzepatide should understand they are using a product without the same regulatory review as the approved drug.

His argument about effort being invisible is genuinely worth taking seriously. The literature on exercise adherence shows that people consistently underestimate how much work goes into visible physique changes, even in individuals using pharmacological support. That blind spot is real.